BNET Industries
- Private
- US
Dow Jones Description
Invitrogen is committed to being the leading provider of novel fluorescent reagents and detection solutions that advance scientific and biomedical research worldwide. Supplying superior Molecular Probes products and services, together with striving for customer and employee satisfaction, will be the driving forces of our organization.
Senior Vice President
Ben BulkleyPeer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
News & Analysis
Filter by
invitrogen corp. and software - All News and Analysis
San Diego public stocks
Index Watch Net Index...
SEC files insider trading complaint
The Securities and Exchange Commission filed insider trading charges against Harry H. Yim, a 45-year-old resident of Vista and a former scientist for Invitrogen Corp., the agency said Oct. 31. The complaint said Yim traded in Invitrogen stock upon hearing of nonpublic information about the company's poor financial results,...
Invitrogen and ScienceXperts Launch Software to Demystify Multicolor Flow Cytometry
CARLSBAD, Calif. & PALO ALTO, Calif. -- Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for disease research and drug discovery, and ScienceXperts, Inc., a provider of software tools for bioscience studies, today announced the launch of CytoGenie[TM], a knowledge-based software tool that simplifies the design of flow...
Invitrogen Corporation Implements Agile Product Portfolio Management and MedImmune to Present at the Cowen & Co. 27th Annual Health Care Conference.
M2 PRESSWIRE-7 March 2007-U.S. Equity News: Invitrogen Corporation Implements Agile Product Portfolio Management and MedImmune to Present at the Cowen & Co. 27th Annual Health Care ConferenceC1994-2007 M2 COMMUNICATIONS LTD RDATE:07032007 City of Industry, CA - Biotechnology industry alert provided by...
Genzyme Begins Phase 2 Pivotal Study of Clolar(R) and Caliper Collaborates with Invitrogen to Develop Fluorescence Kits for Optical Imaging.
M2 PRESSWIRE-29 November 2006-U.S. Equity News: Genzyme Begins Phase 2 Pivotal Study of ClolarR and Caliper Collaborates with Invitrogen to Develop Fluorescence Kits for Optical ImagingC1994-2006 M2 COMMUNICATIONS LTD RDATE:29112006 City of Industry, CA - Biotechnology industry alert provided by ...
Genzyme, MIT, Harvard in Malaria Coalition and Invitrogen Launches New Spin Column Format for ChargeSwitch(R) Nucleic Acid Purification Technology.
M2 PRESSWIRE-19 October 2006-U.S. Equity News: Genzyme, MIT, Harvard in Malaria Coalition and Invitrogen Launches New Spin Column Format for ChargeSwitchR Nucleic Acid Purification TechnologyC1994-2006 M2 COMMUNICATIONS LTD RDATE:19102006 City of Industry, CA - Biotechnology industry alert provided by Equity...
Charles River Laboratories to Present at Thomas Weisel Healthcare Conference and Invitrogen to Present at Bear Stearns 19th Annual Healthcare Conference.
M2 PRESSWIRE-6 September 2006-U.S. Equity News: Charles River Laboratories to Present at Thomas Weisel Healthcare Conference and Invitrogen to Present at Bear Stearns 19th Annual Healthcare ConferenceC1994-2006 M2 COMMUNICATIONS LTD RDATE:06092006 City of Industry, CA - Biotechnology industry alert provided by...
San Diego public stocks
Index Watch Index 2/15/05 2/8/05 Net Chnge %Change San Diego Business 1259.95 1246.70 13.25...
San Diego public stocks
SAN DIEGO PUBLIC STOCKS EXCHANGE TICKER COMPANY NAME PRICE ...
San Diego public stocks
Index Watch Index 10/19/04 10/12/04 San Diego Business Journal Index 1245.37 ...
- 1
- 2
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Ben Bulkley | Senior Vice President |
| David U'Prichard | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Donald W Grimm | Board Member |
| Raymond V. Dittamore | Board of Directors |
| W. Ann Reynolds PhD | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Invitrogen Corporation | Senior Vice President | Current |
| UCSD-CONNECT | Director | Current |
| Organization | Position | Status |
|---|---|---|
| Care Capital, LLC | Venture Partner | Current |
| Red Abbey, LLC | Senior Advisor and Venture Partner | Current |
| University of Glasgow | Honorary Professor | Current |
| Red Abbey, LLC | Advisor | Current |
| Northwestern University | Associate Professor | Current |
| Glasgow University | Honorary Professor | Current |
| Genematrix, Inc. | Board Director | Current |
| Exsar Corporation | Board Director | Current |
| Guilford Pharmaceuticals, Inc. | Director | Current |
| Invitrogen Corporation | Director | Current |
| Cyclacel Limited | Board of Directors | Current |
| GlaxoSmithKline Plc | President | Former |
| SmithKline Beecham Corporation | President of Research and Development | Former |
| Druid Consulting | President | Former |
| Apax Partners Ltd. | Venture Partner | Former |
| Northwestern University School of Medicine | Associate Professor of Pharmacology and Neurobiology | Former |
| Biotechnology Industry Organization | member | Former |
| GlaxoSmithKline Plc | Chairman of Research and Development | Former |
| SmithKline Beecham Corporation | Chairman of R&D | Former |
| Biotechnology Industry Organization | Board Member | Former |
| University of Kansas | Ph.D. in Pharmacology | Former |
| University of Kansas | MS | Former |
| University of Glasgow | B.Sc. in Pharmacology | Former |
| Organization | Position | Status |
|---|---|---|
| Oligoperfect | Founder, Chairman and President, Strategic Design | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Founder, Chairman and President, Strategic Design | Current |
| Resgen Inc. | Founder, Chairman and President, Strategic Design | Current |
| Emiliem, Inc. | Founder, Chairman and President, Strategic Design | Current |
| Hamilton BioVentures | President | Current |
| Molecular Probes | Founder, Chairman and President, Strategic Design | Current |
| Biolayer Corporation Limited | Founder, Chairman and President, Strategic Design | Current |
| Strategic Design | President | Current |
| IDEXX Laboratories, Inc. | Founder, Chairman and President, Strategic Design | Current |
| Seqanswers | Founder, Chairman and President, Strategic Design | Current |
| Microseq | Founder, Chairman and President, Strategic Design | Current |
| Industry Ventures | Founder, Chairman and President, Strategic Design | Current |
| Olink | Founder, Chairman and President, Strategic Design | Current |
| Ionsource, LLC | Founder, Chairman and President, Strategic Design | Current |
| Bioreliance Corporation | Founder, Chairman and President | Current |
| Aegis Therapeutics, LLC | Executive Chairman | Current |
| Strategic Design | Chairman | Current |
| San Diego Regional Chamber of Commerce | Vice Chair | Current |
| Cellzdirect, Inc. | Board of Directors | Current |
| High Throughput Genomics, Inc. | Board of Directors | Current |
| Hamilton BioVentures | Director | Current |
| Intec Telecommunications | Board Member | Current |
| Invitrogen Corporation | Board Member | Current |
| University of Pittsburgh School of Pharmacy | Board Member | Current |
| Angstrom Pharmaceuticals, Inc. | Board of Directors | Current |
| Multiple Peptide Systems Inc | Board of Directors | Current |
| Scripps Clinic | Board Member | Current |
| Hybritech, Inc. | CEO | Former |
| Dura Pharmaceuticals, Inc. | Chief Executive Officer | Former |
| Biosource International, Inc. | Founder, Chairman and President, Strategic Design | Former |
| Hybritech, Inc. | President | Former |
| Copenhagen Capacity | Managing Director | Former |
| Hybritech, Inc. | Director of West Coast Pharmaceutical Sales | Former |
| Eli Lilly and Company | Director of Pharmaceutical Market Research | Former |
| Eli Lilly and Company | management positions | Former |
| U.S. Army | Officer | Former |
| Xcel Pharmaceuticals, Inc. | Former | |
| Verus Pharmaceuticals | Former | |
| Cadence Pharmaceuticals, Inc. | Former | |
| Hybritech, Inc. | Chairman | Former |
| Hybritech | Chairman | Former |
| Biovail Corporation | Chairman | Former |
| Pharmaceutical Market Research | Director | Former |
| Roundtable Inc. | Board of Directors | Former |
| Bioreliance Corporation | Director | Former |
| Somaxon Pharmaceuticals, Inc. | Board of Directors | Former |
| California Healthcare Institute, Inc. | Board of Directors | Former |
| University of Pittsburgh | M.B.A. | Former |
| Pittsburgh Tissue Engineering Initiative, Inc | M.B.A. | Former |
| Baldwin-Wallace College | Master's Degree In Business Administration | Former |
| Pittsburgh Tissue Engineering Initiative, Inc | B.S. In Pharmacy | Former |
| University of Pittsburgh | B.S. In Pharmacy | Former |
Raymond V. Dittamore has served as a Director of the Company since December 2002. Mr. Dittamore is a retired audit partner of Ernst & Young LLP, an international accounting firm. Mr. Dittamore retired in 2001 after 35 years of service with that firm, including 14 years as the managing partner of the firms San Diego office. Mr. Dittamore is also a director of Invitrogen Corporation, Gen-Probe Incorporated, and Digirad Corporation. Mr. Dittamore received a B.S. degree from San Diego State University.
| Organization | Position | Status |
|---|---|---|
| QUALCOMM Incorporated | Board of Directors | Current |
| Molecular Probes | Director | Current |
| Invitrogen Corporation | Board of Directors | Current |
| IDEXX Laboratories, Inc. | Board of Directors | Current |
| Biolayer Corporation Limited | Director | Current |
| Ionsource, LLC | Board of Directors | Current |
| Microseq | Board of Directors | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Board of Directors | Current |
| Industry Ventures | Board of Directors | Current |
| Gen-Probe Inc. | Board of Directors | Current |
| Applied Molecular Evolution, Inc. | Director | Current |
| Ernst & Young | partner | Former |
| Ernst & Young | collaborative editor | Former |
| Digirad Corporation | Board of Directors | Former |
| San Diego State University | B.S. | Former |
| QUALCOMM Incorporated | member | Former |
W. Ann Reynolds, 71, formerly President and Professor of Biology at The University of Alabama at Birmingham, located in Birmingham, Alabama, until 2002. Director since 2006; formerly a Director of OCD since 1993. A graduate of Kansas State Teachers College and the University of Iowa, where she earned a Ph.D. degree, Dr. Reynolds previously served as Chancellor of the City University of New York and as Chancellor of the California State University System. In prior years, she was Provost of the Ohio State University and Professor of Anatomy and Vice Chancellor for Research at the University of Illinois at the Medical Center. Dr. Reynolds is a director of Humana, Inc., Abbott Laboratories, Invitrogen Corporation, and the News-Gazette, Champaign, Illinois.
| Organization | Position | Status |
|---|---|---|
| News Gazette Inc. | Director | Current |
| Humana Inc. | Board of Directors | Current |
| Abbott Laboratories | Board of Directors | Current |
| Owens Corning | Board of Directors | Current |
| Industry Ventures | Board of Directors | Current |
| Business-Higher Education Forum | Member of The Board of The Champaign, Urbana News Gazette | Current |
| Olink | Board of Directors | Current |
| KMG America Corporation | Member of The Board of The Champaign, Urbana News Gazette | Current |
| IDEXX Laboratories, Inc. | Board of Directors | Current |
| Resgen Inc. | Board of Directors | Current |
| Maytag Corporation | Board of Directors | Current |
| Ionsource, LLC | Board of Directors | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Board of Directors | Current |
| Microseq | Board of Directors | Current |
| Abms Member | Board of Directors | Current |
| Invitrogen Corporation | Board of Directors | Current |
| The University of Alabama at Birmingham | President | Former |
| University of Illinois | Professor | Former |
| University of Illinois College of Medicine | Research Professor | Former |
| Emporia State University | M.S. | Former |
| Emporia State University | Bachelors Degree In Biology | Former |
Industry Transcripts by Seeking Alpha
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes


